Cardio Diagnostics Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cardio Diagnostics Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.8K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $34.9K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $17.1K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $950 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $901 | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.50M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($8.38M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($8.38M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($4.66M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($144.8K) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.48M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($8.37M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.24M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($4.55M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($145.3K) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $641.2K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $228.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $145.2K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $40.4K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $31.5K | Mar 31, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.73M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($4.99M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($5.67M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($5.09M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($300.9K) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.3K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $214.8K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $575.7K | Mar 20, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.77M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $10.62M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $4.46M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $6.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $793.1K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.06M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.50M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $33.9K | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.97M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.56M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.96M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.30M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.07M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $60.4K | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.25M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($22.75M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($14.37M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($5.99M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.33M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.83M | Mar 13, 2026 |
| FY2025 | May 13, 2025 | 1.74M | Mar 13, 2026 |
| FY2025 | May 12, 2025 | 52.16M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 1.53M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 20.54M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 9.51M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 1.23M | Mar 31, 2023 |